Anaveon is a clinical stage company committed to transforming immunological insights into life-saving therapies. With a vision to use our expertise in cutting-edge immunology to design and develop treatments that benefit patients and society, the team have the skills to make it happen and are ready to take Anaveon’s first drug into clinical trials.
Anaveon has obtained approval from the FDA to launch first-in-human clinical trial for ANV600.
— ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential —
| Building | C4 |
|---|---|
| Industry | Biotech |
| Research Topics | Cytokines, Immune System Dysfunction, Cancer |
| Employees | 23 |
| Founding year | 2005 |
Home 
About us 
Offer 
News 
